CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. (June 2011)

• Record Type: Journal Article
• Authors: Morse, Michael A; Bradley, Deborah A; Keler, Tibor; Laliberte, Robert J; Green, Jennifer A; Davis, Thomas A; Inman, Brant A
• Is Part Of: Expert review of vaccines. Volume 10:Number 6(2011)
• Page Start: 733
• Page End: 742
• Publication Date: 2011-06
• Subjects: bladder cancer -- cancer immunotherapy -- cancer vaccines -- CDX-1307 -- hCG-ββ -- human chorionic gonadotropin-ββ chain; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/erv.11.20
• Languages: English
• ISSNs: 1476-0584

Abstract

Cancer vaccines have demonstrated clinical benefit, however greater efficacy could be achieved by enhancing their immunogenicity. Owing to cancer vaccines depending on uptake and cross-presentation of tumor antigens by antigen-presenting cells (APCs), we hypothesized that greater immunogenicity would accompany strategies that direct antigen to APC-expressed mannose receptors, initiating a pathway increasing class I and II presentation to T cells. CDX-1307 consists of a human monoclonal antibody targeting the mannose receptor, fused to the human chorionic gonadotropin-ββ chain (hCG-ββ), a tumor antigen frequently expressed by epithelial cancers including bladder cancer. In Phase I studies of cancer patients, CDX-1307 was well tolerated and induced significant hCG-ββ-specific cellular and humoral immune responses when co-administered with GM-CSF and the Toll-like receptor agonists resiquimod and poly-ICLC. An ongoing Phase II trial evaluates CDX-1307 in patients with newly diagnosed, resectable, hCG-ββ-expressing bladder cancer, where low tumor burden and early intervention may provide greater potential for benefit.